Zentalis Pharmaceuticals, Inc.
ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment ofā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.32
Price-2.22%
-$0.03
1Y
Price
Market Cap
$95.371m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$26.865m
-60.2%
1y CAGR-20.0%
3y CAGR-15.0%
5y CAGREarnings
-$149.316m
+10.0%
1y CAGR+9.9%
3y CAGR-4.8%
5y CAGREPS
-$2.08
+10.7%
1y CAGR+19.6%
3y CAGR+9.6%
5y CAGRBook Value
$252.874m
$327.250m
Assets$74.376m
Liabilities$36.708m
DebtDebt to Assets
11.2%
-0.2x
Debt to EBITDAFree Cash Flow
-$134.009m
+21.7%
1y CAGR+4.8%
3y CAGR+2.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company